KDR and breast carcinoma: Molecular docking analysis and molecular dynamics simulations show that the proposed molecules exhibit greatly enhanced binding and inhibitory activity against VEGFR-2, the major breast cancer receptor, compared to the leading known breast cancer drug, Foretnib.